Source: Eur Respir Rev 2015; 24: 582-593
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Bluthgen Maria-Virginia, Besse Benjamin. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. Eur Respir Rev 2015; 24: 582-593

Member's Comments

No comment yet.

Related content which might interest you: Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017 Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 244–259 Year: 2009 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003